Autolus Therapeutics
6A3A.FAutolus Therapeutics in brief
Autolus Therapeutics is a listed company in the Biotechnology industry, based in London, UK. Its market value was $641 M on 1 August 2026, which makes it the 11,490th largest listed company in the world and the 361st largest in the UK on this site. In the year to December 2025 it had sales of $75 M and a net loss of $288 M. Its largest product and service lines by sales in 2025 were License (1%). Its shares trade under the symbol 6A3A.F (Frankfurt).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Autolus Therapeutics
Autolus Therapeutics is a Biopharmaceutical company. The headquarters is in UK.
Autolus Therapeutics timeline
- 2018
- 🔔· approximateInitial public offering on Frankfurt
Events of Autolus Therapeutics from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in UK: #314 (Jan 2020) · #499 (Jan 2021) · #668 (Jan 2022) · #689 (Dec 2022) · #474 (Jul 2023) · #284 (Jan 2024) · #363 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 4.7×
- Price / book
- 3.6×
- Free cash flow yield
- -47.2%
- Net margin (TTM)
- -186.3%
- Operating margin
- -358.9%
- Return on equity
- -143.8%
- Liabilities / assets
- 69.8%
- Net debt
- $-211M
- Revenue growth
- +645.0%
- R&D / revenue
- 156.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $75M | +645.0% | $-271M | $-288M | -381.4% |
| Dec 2024 | $10M | +495.3% | $-241M | $-221M | -2180.4% |
| Dec 2023 | $2M | — | $-180M | $-208M | -12257.6% |
| Dec 2022 | — | — | $-143M | $-149M | — |
| Dec 2021 | — | — | $-141M | $-142M | — |
| Dec 2020 | — | — | $-168M | $-142M | — |
| Dec 2019 | $3M | +106.4% | $-146M | $-124M | -4256.0% |
| Sep 2018 | $1M | — | $-58M | $-45M | -3173.8% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-284M | $19M | $-303M | $-1.08 | — |
| Dec 2024 | $-206M | $22M | $-228M | $-0.86 | — |
| Dec 2023 | $-146M | $11M | $-157M | $-1.20 | — |
| Dec 2022 | $-112M | $11M | $-123M | $-1.57 | — |
| Dec 2021 | $-118M | $9M | $-127M | $-1.97 | — |
| Dec 2020 | $-118M | $15M | $-132M | $-2.76 | — |
| Dec 2019 | $-101M | $18M | $-120M | $-2.88 | — |
| Sep 2018 | $-32M | $9M | $-41M | $-1.42 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $41M (+94.6% on a year earlier), net income $-55M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Aug 3, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 3, 20268-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale
- Jun 29, 20268-KCurrent reportShareholder vote
- Jun 9, 20268-KCurrent reportOther events
- May 14, 202610-QQuarterly report · period to Mar 2026
- May 14, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Apr 29, 20268-KCurrent reportRestructuring costs · Regulation FD disclosure
- Apr 16, 20268-KCurrent reportAuditor change
Official filings of Autolus Therapeutics with the US Securities and Exchange Commission.
Annual results
- Revenue
- $75 M
- Operating income
- $-271 M
- Net income
- $-288 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $589 M
- Total liabilities
- $411 M
- Total equity
- $178 M
As of December-2025
Top 91 institutional investors in Autolus Therapeutics#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Mak Capital One LLC | 30,528,859 | -3,092,628 (-9.20%) | 8.66% | $59 M | Nov 16, 2026 |
| 2 | Blackstone Inc. | 20,485,611 | 0 (0.00%) | 5.81% | $40 M | Nov 16, 2026 |
| 3 | Syncona Portfolio Ltd | 16,640,720 | 0 (0.00%) | 4.72% | $32 M | Nov 5, 2026 |
| 4 | Armistice Capital, LLC | 13,750,000 | -1,250,000 (-8.33%) | 3.90% | $27 M | Nov 16, 2026 |
| 5 | Tetragon Partners GP Ltd | 9,500,000 | 0 (0.00%) | 2.70% | $18 M | Nov 16, 2026 |
| 6 | Schroder Investment Management Group | 6,130,793 | -1,702,489 (-21.73%) | 1.74% | $12 M | Nov 16, 2026 |
| 7 | Frazier Life Sciences Management, L.P. | 4,447,910 | 0 (0.00%) | 1.26% | $9 M | Nov 16, 2026 |
| 8 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 3,361,156 | 0 (0.00%) | 0.95% | $7 M | Nov 13, 2026 |
| 9 | Laurion Capital Management LP | 3,316,626 | 0 (0.00%) | 0.94% | $6 M | Oct 30, 2026 |
| 10 | Renaissance Technologies LLC | 2,492,900 | +508,200 (+25.61%) | 0.71% | $5 M | Nov 12, 2026 |
| 11 | Millennium Management LLC | 2,164,182 | +939,364 (+76.69%) | 0.61% | $4 M | Nov 16, 2026 |
| 12 | Morgan Stanley | 2,105,535 | +844,703 (+67.00%) | 0.60% | $4 M | Nov 13, 2026 |
| 13 | Citadel Advisors LLC | 1,630,469 | +934,579 (+134.30%) | 0.46% | $3 M | Nov 16, 2026 |
| 14 | BlackRock, Inc. | 1,510,455 | -93,003 (-5.80%) | 0.43% | $3 M | Nov 13, 2026 |
| 15 | UBS Group AG | 1,429,205 | -87,786 (-5.79%) | 0.41% | $3 M | Nov 10, 2026 |
| 16 | Cetera Investment Advisers | 1,235,300 | +77,976 (+6.74%) | 0.35% | $2 M | Nov 13, 2026 |
| 17 | Walleye Capital LLC | 1,214,501 | New | 0.34% | $2 M | Nov 13, 2026 |
| 18 | Bank Of America Corp /de/ | 1,002,832 | -602,260 (-37.52%) | 0.28% | $2 M | Nov 16, 2026 |
| 19 | Goldman Sachs Group Inc | 972,969 | +859,413 (+756.82%) | 0.28% | $2 M | Nov 16, 2026 |
| 20 | Jpmorgan Chase & Co | 897,639 | -15,600 (-1.71%) | 0.25% | $2 M | Nov 12, 2026 |
| 21 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 717,623 | New | 0.20% | $1 M | Nov 16, 2026 |
| 22 | Privium Fund Management B.V. | 469,490 | +106,060 (+29.18%) | 0.13% | $1 M | Nov 3, 2026 |
| 23 | Hennion & Walsh Asset Management, Inc. | 419,217 | -32,186 (-7.13%) | 0.12% | $1 M | Oct 13, 2026 |
| 24 | EDENTREE ASSET MANAGEMENT Ltd | 300,000 | 0 (0.00%) | 0.09% | $1 M | Nov 16, 2026 |
| 25 | Acadian Asset Management LLC | 286,711 | +258,582 (+919.27%) | 0.08% | $1 M | Nov 9, 2026 |
Show all 91: investors 26 to 91
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Tidal Investments LLC | 273,617 | New | 0.08% | $1 M | Nov 13, 2026 |
| 27 | Aquatic Capital Management LLC | 261,360 | New | 0.07% | $1 M | Nov 16, 2026 |
| 28 | Qube Research & Technologies Ltd | 261,082 | New | 0.07% | $1 M | Nov 13, 2026 |
| 29 | Quadrature Capital Ltd | 224,193 | +109,310 (+95.15%) | 0.06% | $0 M | Nov 13, 2026 |
| 30 | Jane Street Group, LLC | 212,313 | -87,549 (-29.20%) | 0.06% | $0 M | Nov 12, 2026 |
| 31 | Wells Fargo & Company/mn | 210,922 | -1,670 (-0.79%) | 0.06% | $0 M | Nov 16, 2026 |
| 32 | Erste Asset Management GmbH | 195,000 | 0 (0.00%) | 0.06% | $0 M | Nov 12, 2026 |
| 33 | DAFNA Capital Management LLC | 179,316 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 34 | HRT Financial LP | 164,950 | +75,587 (+84.58%) | 0.05% | $0 M | Nov 13, 2026 |
| 35 | Voleon Capital Management LP | 156,250 | New | 0.04% | $0 M | Nov 16, 2026 |
| 36 | Nano Cap New Millennium Growth Fund L P | 150,000 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 37 | Point72 Asset Management, L.P. | 134,420 | +63,193 (+88.72%) | 0.04% | $0 M | Nov 16, 2026 |
| 38 | Susquehanna International Group, LLP | 132,727 | -44,505 (-25.11%) | 0.04% | $0 M | Nov 16, 2026 |
| 39 | Graham Capital Management, L.P. | 122,726 | New | 0.03% | $0 M | Nov 16, 2026 |
| 40 | Clearstead Advisors, LLC | 121,107 | 0 (0.00%) | 0.03% | $0 M | Nov 6, 2026 |
| 41 | Two Sigma Investments, LP | 106,889 | New | 0.03% | $0 M | Nov 16, 2026 |
| 42 | State Street Corp | 101,955 | +17,546 (+20.79%) | 0.03% | $0 M | Nov 12, 2026 |
| 43 | Engineers Gate Manager LP | 100,307 | New | 0.03% | $0 M | Nov 16, 2026 |
| 44 | Leonteq Securities AG | 100,000 | 0 (0.00%) | 0.03% | $0 M | Oct 29, 2026 |
| 45 | Aigen Investment Management, LP | 82,392 | +64,555 (+361.92%) | 0.02% | $0 M | Nov 16, 2026 |
| 46 | Axq Capital, LP | 77,197 | New | 0.02% | $0 M | Nov 12, 2026 |
| 47 | Invesco Ltd. | 64,921 | -1,526 (-2.30%) | 0.02% | $0 M | Nov 12, 2026 |
| 48 | XTX Topco Ltd | 57,434 | -230,022 (-80.02%) | 0.02% | $0 M | Nov 16, 2026 |
| 49 | SmartHarvest Portfolios, LLC | 48,639 | -14,963 (-23.53%) | 0.01% | $0 M | Oct 26, 2026 |
| 50 | WINTON GROUP Ltd | 48,000 | New | 0.01% | $0 M | Nov 12, 2026 |
| 51 | LPL Financial LLC | 42,745 | +120 (+0.28%) | 0.01% | $0 M | Nov 6, 2026 |
| 52 | Squarepoint Ops LLC | 38,693 | New | 0.01% | $0 M | Nov 9, 2026 |
| 53 | HighPoint Advisor Group LLC | 37,000 | -20,000 (-35.09%) | 0.01% | $0 M | Nov 9, 2026 |
| 54 | China Universal Asset Management Co., Ltd. | 36,602 | +4,677 (+14.65%) | 0.01% | $0 M | Oct 28, 2026 |
| 55 | Blair William & Co/il | 36,500 | +21,500 (+143.33%) | 0.01% | $0 M | Nov 10, 2026 |
| 56 | Rhumbline Advisers | 36,295 | -2,469 (-6.37%) | 0.01% | $0 M | Nov 10, 2026 |
| 57 | Virtu Financial LLC | 33,057 | +9,500 (+40.33%) | 0.01% | $0 M | Nov 17, 2026 |
| 58 | R Squared Ltd | 31,360 | -5,066 (-13.91%) | 0.01% | $0 M | Nov 6, 2026 |
| 59 | Rathbones Group PLC | 28,050 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 60 | Osaic Holdings, Inc. | 27,724 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 61 | Waverly Advisors, LLC | 26,870 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 62 | Caitong International Asset Management Co., Ltd | 26,145 | +9,944 (+61.38%) | 0.01% | $0 M | Oct 29, 2026 |
| 63 | Manufacturers Life Insurance Company, The | 25,851 | +659 (+2.62%) | 0.01% | $0 M | Nov 13, 2026 |
| 64 | Delaney Dennis R | 24,000 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 65 | Barclays PLC | 18,953 | +7,014 (+58.75%) | 0.01% | $0 M | Nov 6, 2026 |
| 66 | Vise Technologies, Inc. | 18,084 | New | 0.01% | $0 M | Oct 29, 2026 |
| 67 | Marex Group Ltd | 17,857 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 68 | GAMMA Investing LLC | 16,425 | +926 (+5.97%) | 0.00% | $0 M | Oct 8, 2026 |
| 69 | SIH Partners, LLLP | 16,254 | +1,367 (+9.18%) | 0.00% | $0 M | Nov 16, 2026 |
| 70 | Lido Advisors, LLC | 16,036 | +527 (+3.40%) | 0.00% | $0 M | Nov 4, 2026 |
| 71 | Private Advisor Group, LLC | 14,220 | New | 0.00% | $0 M | Nov 10, 2026 |
| 72 | Apollon Wealth Management, LLC | 14,003 | -16 (-0.11%) | 0.00% | $0 M | Oct 23, 2026 |
| 73 | Geode Capital Management, LLC | 13,356 | -110,578 (-89.22%) | 0.00% | $0 M | Nov 6, 2026 |
| 74 | Dumont & Blake Investment Advisors LLC | 13,000 | -1,000 (-7.14%) | 0.00% | $0 M | Oct 28, 2026 |
| 75 | Vanguard Personalized Indexing Management, LLC | 12,743 | -4,217 (-24.86%) | 0.00% | $0 M | Nov 16, 2026 |
| 76 | Claro Advisors Inc. | 12,500 | 0 (0.00%) | 0.00% | $0 M | Nov 2, 2026 |
| 77 | Simplicity Wealth,LLC | 10,838 | New | 0.00% | $0 M | Oct 23, 2026 |
| 78 | Independent Advisor Alliance | 10,650 | -11,692 (-52.33%) | 0.00% | $0 M | Nov 10, 2026 |
| 79 | Mirae Asset Global Investments Co., Ltd. | 10,251 | +1,280 (+14.27%) | 0.00% | $0 M | Oct 29, 2026 |
| 80 | Meridian Financial Partners LLC | 10,000 | New | 0.00% | $0 M | Oct 23, 2026 |
| 81 | Wealth Effects LLC | 10,000 | 0 (0.00%) | 0.00% | $0 M | Oct 23, 2026 |
| 82 | BNP Paribas Financial Markets | 7,582 | +700 (+10.17%) | 0.00% | $0 M | Nov 12, 2026 |
| 83 | Tower Research Capital LLC (TRC) | 6,528 | -1,005 (-13.34%) | 0.00% | $0 M | Nov 16, 2026 |
| 84 | TrinityBridge Ltd | 6,300 | 0 (0.00%) | 0.00% | $0 M | Oct 30, 2026 |
| 85 | Citigroup Inc | 5,331 | +613 (+12.99%) | 0.00% | $0 M | Nov 4, 2026 |
| 86 | GF Fund Management Co. LTD. | 4,523 | +369 (+8.88%) | 0.00% | $0 M | Oct 26, 2026 |
| 87 | Pinnacle Financial Group, Inc. | 1,000 | — | 0.00% | $0 M | Nov 16, 2026 |
| 88 | Caldwell Sutter Capital, Inc. | 500 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 89 | Byrne Asset Management LLC | 100 | 0 (0.00%) | 0.00% | $0 M | Oct 6, 2026 |
| 90 | SBI Securities Co., Ltd. | 55 | +1 (+1.85%) | 0.00% | $0 M | Oct 22, 2026 |
| 91 | Allworth Financial LP | 50 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
Mutual funds holding Autolus Therapeutics#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 1.43 M | $2 M | — | 0.03% | +8.1% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 120,878 | $0 M | — | <0.01% | +9.3% | May 31, 2026 |
| 🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc. | 84,409 | $0 M | — | 0.02% | +1.0% | Jun 30, 2026 |
| 🇺🇸 ActivePassive International Equity ETFTrust for Professional Managers | 22,753 | $0 M | — | <0.01% | new | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Autolus Therapeutics#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Cintia PiccinaU.S. CCO & Country Gen Manager | Sell | -6,713 | $2.340 | $16 K | 13,287 | Form 4 |
| filed | Cintia PiccinaU.S. CCO & Country Gen Manager | Option exercise | +20,000 | $2.350 | $47 K | 20,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Autolus Therapeutics#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 2,210 shares at $1.60
- : 620 shares at $1.86
- : 5,757 shares at $1.95
- : 56 shares at $2.29
- : 58 shares at $2.31
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Autolus Therapeutics scorecard#
Passes 2 of the 12 checks that could be worked out: strongest in growth (1 of 3), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth1 of 3
- ✓Revenue grew in the newest year645.0%Revenue up 645.0% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.08 vs -0.86Diluted EPS -1.08 in fiscal 2025 against -0.86 the year before (report's currency).
- ✗Net income higher than five years earlier-$288 M-$288 M in fiscal 2025 against -$142 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 4
- ✗Profitable in the newest year-$288 MNet income -$288 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-358.9%-358.9% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-95.0%-95.0% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 4
- ✓Short-term assets cover short-term liabilities5.9×Current ratio 5.94 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-7.4×Operating income -7.4 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-3.01Z-score -3.01 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year4.3%Diluted shares up 4.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Autolus Therapeutics's statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -358.9% | -60.5% | |
| Net margin | -381.4% | -68.9% | |
| Return on equity | -95.0% | -61.0% | |
| Revenue growth | 645.0% | 15.8% | |
| Free cash flow margin | -401.4% | -61.5% |
2of 8on the Piotroski tests of financial strength
- Net loss of $288 million, the 10th loss-making year in a row.
- Free cash flow was negative: -$303 million.
- Operating income covers the interest bill only -7.4 times.
Autolus Therapeutics: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Sep 30, 2018 | FY 2017to Sep 30, 2017 | FY 2016to Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 75+645%100% | 10+496%100% | 1.7—100% | — | — | — | 2.9+107%100% | 1.4−16.9%100% | 1.7+39.7%100% | 1.2—100% | |
| Cost of revenue | 96+746%128% | 11—113% | 0—0.0% | — | — | — | — | — | — | — | |
| Research and development | 118−15.0%156% | 138+6.1%1368% | 130+11.2%7684% | 117r142+5.9%— | 111r135−17.8%— | 135+28.0%— | 105+192%3625% | 36+126%2569% | 16+53.4%946% | 10—861% | |
| Selling, general and administrative | 132+29.6%175% | 102r101+118%1005% | 47—2753% | — | — | — | — | — | — | — | |
| General and administrative | — | — | 47+46.5%2753% | 32+0.1%— | 32−8.9%— | 35−11.4%— | 39+73.1%1357% | 23+150%1620% | 9.1+76.6%537% | 5.2—425% | |
| Operating expenses | — | — | — | — | — | — | — | 58+146%4089% | 23+62.9%1383% | 14—1186% | |
| Operating income | −271—−359% | −241—−2386% | −180—−10583% | −143r−168—— | −141r−165—— | −168—— | −146—−5023% | −58—−4089% | −23—−1383% | — | |
| Interest and finance income | 19−41.3%25.2% | 32+140%320% | 14+691%795% | 1.7+552%— | 0.3−51.1%— | 0.5−78.9%— | 2.5+65.9%87.4% | 1.5+1724%109% | 0.1+12.0%5.0% | 0.1—6.2% | |
| Interest expense and finance costs | 37+295%48.6% | 9.3−79.4%91.8% | 45+406%2654% | 8.9+706%— | 1.1—— | 0—— | 0—0.0% | — | — | — | |
| Other non-operating income (expense) | −15−167%−19.9% | 22—220% | −29—−1690% | −5.2—— | −1.0−152%— | 1.9−73.2%— | 7.1+28.2%243% | 5.5+14379%391% | 0.0−22.4%2.2% | 0.0—4.0% | |
| Income before tax | −286—−379% | −219—−2165% | −208—−12273% | −149r−173—— | −142r−166—— | −166—— | −139—−4780% | −52—−3698% | −23—−1381% | −14—−1182% | |
| Income tax | 2.0+29.1%2.6% | 1.5—15.1% | −0.0r−0.0−107%−1.1% | 0.3r−24+369%— | 0.1r−24—— | −24—— | −15—−521% | −7.3—−517% | −3.7—−216% | −1.8—−147% | |
| Net income attributable to shareholders | −288—−381% | −221—−2180% | −208—−12272% | −149—— | −142—— | −142—— | −124—−4259% | −45—−3181% | −20—−1165% | −13—−1035% | |
| Earnings per share, basic | -1.08—— | -0.86—— | -1.20—— | -1.57—— | -1.97—— | -2.76—— | -2.88—— | -1.42—— | -1.43—— | -1.26—— | |
| Earnings per share, diluted | -1.08—— | -0.86—— | -1.20—— | -1.57—— | -1.97—— | -2.76—— | -2.88—— | -1.42—— | -1.43—— | -1.26—— | |
| Shares, weighted average (basic) | 266+4.3%— | 255+46.7%— | 174+83.1%— | 95+31.8%— | 72+39.8%— | 52+19.7%— | 43—— | — | — | — | |
| Shares, weighted average (diluted) | 266+4.3%— | 255+46.7%— | 174+83.1%— | 95+31.8%— | 72+39.8%— | 52+19.7%— | 43+36.5%— | 32+129%— | 14+38.8%— | 9.9—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 104−54.2%17.7% | 227−5.1%29.0% | 240−37.4%63.8% | 382+23.2%78.0% | 310r310+102%76.5% | 153−27.2%52.1% | 211−14.7%69.4% | 247r247+80.2%90.4% | 137+389%92.2% | 28—— | |
| Short-term investments | 197−45.5%33.4% | 361—46.1% | 0—0.0% | — | — | — | — | — | — | — | |
| Receivables | 24+160060%4.1% | 0.0−86.2%0.0% | 0.1−9.9%0.0% | 0.1—0.0% | 0—0.0% | — | — | — | — | — | |
| Inventory | 33+703%5.6% | 4.1—0.5% | 0—0.0% | — | — | — | — | — | — | — | |
| Other current assets | 0−100%0.0% | 1.6r1.6—0.2% | 0r0−100%0.0% | 0.2−15.4%0.0% | 0.2—0.1% | 0−100%0.0% | 0.3−61.1%0.1% | 0.7—0.3% | 0—0.0% | — | |
| Current assets | 436−34.0%74.0% | 661+140%84.4% | 275−35.3%73.3% | 426+22.7%86.8% | 347+76.1%85.5% | 197−21.0%66.9% | 249−3.9%82.1% | 259+82.0%94.9% | 142—95.8% | — | |
| Property, plant and equipment | 64+28.3%10.8% | 50+42.1%6.3% | 35−1.0%9.3% | 35+5.0%7.2% | 34−11.8%8.3% | 38+35.1%12.9% | 28+108%9.3% | 14+119%5.0% | 6.2—4.2% | — | |
| Right-of-use (leased) assets | 65+17.0%11.0% | 55−8.7%7.1% | 61+162%16.2% | 23+23.6%4.7% | 19−63.6%4.6% | 52+121%17.5% | 23—7.7% | — | — | — | |
| Other intangible assets | 20+60.1%3.4% | 12—1.6% | 0—0.0% | 0−100%0.0% | 0.1−58.9%0.0% | 0.2−37.8%0.1% | 0.3−36.3%0.1% | 0.4—0.1% | 0—0.0% | — | |
| Total assets | 589−24.7%100% | 783+109%100% | 375−23.4%100% | 490+20.9%100% | 406+37.8%100% | 294−3.1%100% | 304+11.1%100% | 273+83.8%100% | 149—100% | — | |
| Accounts payable | 3.1+56.6%0.5% | 2.0+1812%0.3% | 0.1−80.6%0.0% | 0.5+23.2%0.1% | 0.4−81.0%0.1% | 2.3+111%0.8% | 1.1−64.6%0.4% | 3.0+56.0%1.1% | 1.9—1.3% | — | |
| Current liabilities | 73+20.9%12.5% | 61+35.8%7.8% | 45−3.5%11.9% | 46+62.4%9.5% | 29−15.1%7.0% | 34+34.6%11.4% | 25+45.8%8.2% | 17+241%6.3% | 5.0—3.4% | — | |
| Long-term debt | — | — | — | — | — | — | 0−100%0.0% | 0.4−50.2%0.1% | 0.8—0.5% | — | |
| Lease liabilities (non-current) | 67+34.6%11.3% | 50+3.6%6.3% | 48+149%12.8% | 19+16.2%3.9% | 17−67.3%4.1% | 51+113%17.2% | 24—7.8% | — | — | — | |
| Total liabilities | 411+15.6%69.8% | 355+34.7%45.4% | 264+37.7%70.3% | 192+108%39.1% | 92+9.5%22.7% | 84+72.9%28.6% | 49+174%16.0% | 18+193%6.5% | 6.1—4.1% | — | |
| Retained earnings | −1,387—−235% | −1,099—−140% | −879—−234% | −670—−137% | −521—−129% | −379—−129% | −237—−78.1% | −93—−33.9% | −48—−32.2% | — | |
| Shareholders' equity | 178−58.3%30.2% | 427+283%54.6% | 111−62.7%29.7% | 299−4.7%60.9% | 313+49.2%77.3% | 210−17.6%71.4% | 255−0.2%84.0% | 255+79.1%93.5% | 143+365%95.9% | 31—— | |
| Total liabilities and equity | 589−24.7%100% | 783+109%100% | 375−23.4%100% | 490+20.9%100% | 406+37.8%100% | 294−3.1%100% | 304+11.1%100% | 273+83.8%100% | 149—100% | — | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 8.3+9.8%11.0% | 7.6+15.1%74.6% | 6.6−11.5%387% | 7.4−12.2%— | 8.5+49.5%— | 5.7+22.7%— | 4.6—159% | — | — | — | |
| Share-based compensation | 14−6.7%19.2% | 15+38.1%153% | 11r11−6.7%660% | 12+20.9%— | 9.9−50.4%— | 20−34.1%— | 30+349%1045% | 6.8+115%481% | 3.2+39.7%186% | 2.3—186% | |
| Cash from operating activities | −284—−376% | −206—−2038% | −146—−8574% | −112—— | −118—— | −118—— | −101—−3490% | −32—−2241% | −16—−966% | −9.8—−813% | |
| Capital expenditure | −19—−25.3% | −22—−218% | −11—−647% | −11—— | −8.9—— | −15—— | −18—−631% | −9.1—−648% | −2.9—−170% | −1.9—−153% | |
| Intangible assets bought | −8.1—−10.7% | −13—−126% | 0—0.0% | — | 0—— | 0—— | −0.3—−11.2% | −0.4—−29.3% | 0—0.0% | 0—0.0% | |
| Cash from investing activities | 158—210% | −395—−3899% | −11—−647% | −11—— | −8.9—— | −15—— | −19—−642% | −9.5—−677% | −2.9—−170% | −1.9—−153% | |
| Shares issued | 0−100%0.0% | 550—5435% | 0−100%0.0% | 164−33.4%— | 246+208%— | 80r74−31.2%— | 116r109−26.1%3986% | 157+22.9%11153% | 128+296%7542% | 32—2659% | |
| Cash from financing activities | −4.3−101%−5.8% | 590—5826% | −0.9−100%−52.0% | 224−21.3%— | 284+282%— | 74−31.6%— | 109−30.6%3744% | 157+22.9%11153% | 128+296%7542% | 32—2659% | |
| Exchange-rate effect on cash | 6.3—8.3% | −0.3−102%−2.6% | 15—885% | −28—— | −0.8−211%— | 0.7−86.9%— | 5.2—178% | −5.8−1140%−415% | 0.6—33.1% | −2.7—−220% | |
| Change in cash | −123—−163% | −12—−114% | −142−298%−8388% | 72−54.0%— | 157—— | −57—— | −6.1−106%−211% | 110+0.9%7819% | 109+511%6439% | 18—1473% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 137+169%100% | 41+94.6%100% | 46+118%100% | 26+192%100% | 24*+83655%100% | 21—100% | 21—100% | 9.0−11.0%100% | 0.0*—100% | 0—— | 0—— | 10—100% | — | |
| Cost of revenue | 88+7.1%64.2% | 18−37.4%43.5% | 20−16.3%44.8% | 25+36.9%93.7% | 25*+122%104% | 29—135% | 24—117% | 18—200% | 11*—39266% | 0—— | 0—— | 0—0.0% | — | |
| Research and development | 116+2.4%84.1% | 31+10.8%74.9% | 28+1.7%61.1% | 21−20.7%80.9% | 36*+15.6%147% | 28−30.8%132% | 27−25.1%131% | 27−12.8%298% | 31*−17.9%106310% | 40—— | 37—— | 31—304% | 38r25*—— | |
| Selling, general and administrative | 153+17.2%111% | 36−0.9%87.2% | 41+36.0%90.1% | 40+35.3%152% | 36r36*+4.3%147% | 36+32.7%171% | 30+38.2%145% | 30r30+62.5%329% | 34r34*—118321% | 27—— | 22—— | 18—180% | — | |
| General and administrative | — | — | — | — | — | — | — | — | — | 27—— | 22—— | 18—180% | 16*—— | |
| Operating income | −219—−160% | −44—−106% | −44—−95.9% | −60—−227% | −72*—−298% | −72—−338% | −61—−293% | −65—−726% | −76*—−261600% | −68—— | −59—— | −39—−384% | −53r−41*—— | |
| Interest and finance income | 9.7−58.2%7.1% | 2.1−51.6%5.1% | 1.9−64.1%4.1% | 2.5−59.8%9.4% | 3.2*−56.7%13.3% | 4.4−47.3%20.7% | 5.2−45.8%25.0% | 6.1−11.5%68.3% | 7.4*+147%25679% | 8.3—— | 9.7—— | 6.9—68.7% | 3.0*—— | |
| Interest expense and finance costs | 46—33.3% | 15+38.1%35.2% | −2.7—−5.9% | 11+9.7%42.4% | 23*—94.0% | 11−1.6%49.6% | −6.8−167%−32.6% | 10−47.4%113% | — | 11—— | 10—— | 19—191% | 30*—— | |
| Other non-operating income (expense) | −37−169%−27.0% | −12—−29.2% | 5.2−62.1%11.4% | −11—−42.8% | −19*−138%−78.4% | −7.0—−32.9% | 14+1835%65.5% | −2.7—−30.0% | 50*—171448% | −14—— | 0.7—— | −14—−138% | −24*—— | |
| Income before tax | −256—−187% | −56—−135% | −39—−84.6% | −71—−270% | −92*—−377% | −79—−371% | −48—−227% | −68—−756% | −26*—−90152% | −82—— | −58—— | −53—−522% | −77r−65*—— | |
| Income tax | −0.3−107%−0.3% | −0.5−192%−1.2% | 0.5+17.1%1.0% | 0.9−61.2%3.3% | −1.2*−181%−4.9% | 0.5+2318%2.5% | 0.4+678%1.9% | 2.2—24.8% | 1.5*—5041% | 0.0—— | 0.1—— | −0.0—−0.1% | −0.0r12*—— | |
| Net income attributable to shareholders | −256—−186% | −55—−134% | −39—−85.6% | −72—−273% | −90*—−372% | −79—−373% | −48—−229% | −70—−781% | −28*—−95193% | −82—— | −58—— | −53—−522% | −77*—— | |
| Earnings per share, basic | — | -0.21—— | -0.15—— | -0.27—— | — | -0.30—— | -0.18—— | -0.26—— | — | -0.31—— | -0.22—— | -0.24—— | — | |
| Earnings per share, diluted | — | -0.21—— | -0.15—— | -0.27—— | — | -0.30—— | -0.18—— | -0.26—— | — | -0.31—— | -0.22—— | -0.24—— | — | |
| Shares, weighted average (basic) | 266+0.0%— | 266+0.0%— | 266+0.0%— | 266+0.0%— | — | 266+0.0%— | 266+0.0%— | 266+19.8%— | — | 266—— | 266—— | 222—— | — | |
| Shares, weighted average (diluted) | 266+0.0%— | 266+0.0%— | 266+0.0%— | 266+0.0%— | — | 266+0.0%— | 266+0.0%— | 266+19.8%— | — | 266—— | 266—— | 222—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 245—46.9% | 245+185%46.9% | 171+38.4%34.8% | 131+36.7%24.8% | 104−54.2%17.7% | 86−86.9%13.0% | 124−82.5%17.2% | 96−87.4%12.8% | 227−5.1%29.0% | 657—79.4% | 706—82.7% | 759—84.1% | 240—63.8% | |
| Short-term investments | 3.0—0.6% | 3.0−98.9%0.6% | 30−90.9%6.1% | 99−76.6%18.7% | 197−45.5%33.4% | 281—42.5% | 330—45.8% | 421—56.4% | 361—46.1% | — | — | — | 0—0.0% | |
| Receivables | 38—7.3% | 38—7.3% | 44—9.0% | 28—5.2% | 24+160060%4.1% | — | — | — | 0.0−86.2%0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0.1—0.0% | |
| Inventory | 35—6.7% | 35+26.3%6.7% | 33+39.6%6.8% | 33+127%6.3% | 33+703%5.6% | 28—4.2% | 24—3.3% | 15—2.0% | 4.1—0.5% | — | — | — | 0—0.0% | |
| Other current assets | 44—8.4% | 44−48.6%8.4% | 55—11.2% | 77+4651%14.6% | 0−100%0.0% | 85+43.2%12.9% | 0−100%0.0% | 1.6−96.4%0.2% | 1.6r1.6—0.2% | 60—7.2% | 52—6.0% | 45—5.0% | 0r0—0.0% | |
| Current assets | 367—70.1% | 367−28.7%70.1% | 336−41.5%68.1% | 369−40.1%70.0% | 436−34.0%74.0% | 515−28.3%77.7% | 574−24.3%79.6% | 616−23.4%82.5% | 661+140%84.4% | 718—86.8% | 759—88.9% | 804—89.2% | 275—73.3% | |
| Property, plant and equipment | 60—11.4% | 60−10.8%11.4% | 61−8.9%12.3% | 62+6.8%11.7% | 64+28.3%10.8% | 67+51.0%10.1% | 66+102%9.2% | 58+73.5%7.8% | 50+42.1%6.3% | 44—5.3% | 33—3.8% | 33—3.7% | 35—9.3% | |
| Right-of-use (leased) assets | 73—14.0% | 73+29.7%14.0% | 74+26.4%15.0% | 73+29.0%13.8% | 65+17.0%11.0% | 57−6.4%8.6% | 59+1.6%8.1% | 56−4.9%7.5% | 55−8.7%7.1% | 61—7.3% | 58—6.8% | 59—6.6% | 61—16.2% | |
| Other intangible assets | 18—3.5% | 18−10.9%3.5% | 19+43.3%3.8% | 19+52.1%3.6% | 20+60.1%3.4% | 20—3.1% | 13—1.8% | 12—1.7% | 12—1.6% | — | — | — | 0—0.0% | |
| Total assets | 523—100% | 523−21.0%100% | 493−31.6%100% | 527−29.4%100% | 589−24.7%100% | 662−20.0%100% | 721−15.5%100% | 746−17.2%100% | 783+109%100% | 827—100% | 854—100% | 901—100% | 375—100% | |
| Accounts payable | 1.0—0.2% | 1.0−90.6%0.2% | 1.4−74.7%0.3% | 1.9−58.0%0.4% | 3.1+56.6%0.5% | 11+673%1.7% | 5.4+393%0.8% | 4.5+219%0.6% | 2.0+1812%0.3% | 1.4—0.2% | 1.1—0.1% | 1.4—0.2% | 0.1—0.0% | |
| Current liabilities | 99—18.9% | 99+18.8%18.9% | 69+0.9%13.9% | 64−4.5%12.1% | 73+20.9%12.5% | 83+58.3%12.5% | 68+66.6%9.5% | 67+51.4%8.9% | 61+35.8%7.8% | 52—6.3% | 41—4.8% | 44—4.9% | 45—11.9% | |
| Lease liabilities (non-current) | 77—14.7% | 77+26.2%14.7% | 78+26.9%15.8% | 77+40.5%14.6% | 67+34.6%11.3% | 61+25.4%9.2% | 61+33.8%8.5% | 55+17.7%7.3% | 50+3.6%6.3% | 49—5.9% | 46—5.4% | 47—5.2% | 48—12.8% | |
| Total liabilities | 496—94.8% | 496+25.0%94.8% | 418+11.7%84.8% | 418+11.5%79.4% | 411+15.6%69.8% | 396+13.1%59.9% | 375+15.0%51.9% | 375+17.5%50.3% | 355+34.7%45.4% | 351—42.4% | 326—38.2% | 319—35.4% | 264—70.3% | |
| Retained earnings | −1,553—−297% | −1,553—−297% | −1,497—−304% | −1,458—−277% | −1,387—−235% | −1,296—−196% | −1,217—−169% | −1,169—−157% | −1,099—−140% | −1,072—−130% | −990—−116% | −931—−103% | −879—−234% | |
| Shareholders' equity | 27—5.2% | 27−89.7%5.2% | 75−78.4%15.2% | 109−70.7%20.6% | 178−58.3%30.2% | 265−44.3%40.1% | 346−34.4%48.1% | 371−36.2%49.7% | 427+283%54.6% | 477—57.6% | 528—61.8% | 582—64.6% | 111—29.7% | |
| Total liabilities and equity | 523—100% | 523−21.0%100% | 493−31.6%100% | 527−29.4%100% | 589−24.7%100% | 662−20.0%100% | 721−15.5%100% | 746−17.2%100% | 783+109%100% | 827—100% | 854—100% | 901—100% | 375—100% | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 8.9+10.0%6.5% | 2.4*+13.8%5.7% | 2.2*+3.7%4.7% | 2.2+10.9%8.4% | 2.1*+11.9%8.8% | 2.1*+7.3%9.8% | 2.1*+9.9%10.0% | 2.0+10.3%22.2% | 1.9*+7.9%6603% | 1.9*—— | 1.9*—— | 1.8—17.9% | 1.8*—— | |
| Share-based compensation | 14−16.8%10.4% | 2.7−28.8%6.6% | 4.6+7.0%10.1% | 3.6+24.3%13.6% | 3.4*−44.8%14.2% | 3.8−4.6%18.1% | 4.3+46.3%20.5% | 2.9+25.5%31.9% | 6.2*+91.4%21493% | 4.0—— | 2.9—— | 2.3—22.6% | 3.3r3.3*—— | |
| Cash from operating activities | −176—−128% | −19*—−44.9% | −25*—−54.9% | −65—−249% | −67*—−277% | −68*—−320% | −73*—−348% | −76—−841% | −38*—−130807% | −77*—— | −51*—— | −41—−401% | −25*—— | |
| Capital expenditure | — | −1.2*—−3.0% | −0.9*—−2.0% | −2.7—−10.3% | — | −4.4*—−20.8% | −7.3*—−34.8% | −8.2—−91.8% | −11*—−38317% | −9.6*—— | −0.8*—— | −0.5—−5.3% | −1.5*—— | |
| Intangible assets bought | — | — | — | — | 0*—0.0% | — | — | — | −13*—−43945% | — | — | — | — | |
| Cash from investing activities | 277—201% | 26*−26.9%63.0% | 68*−29.2%149% | 96—367% | 87*—356% | 36*—168% | 96*—458% | −60—−663% | −384*—−1322721% | −9.6*—— | −0.8*—— | −0.5—−5.3% | −1.5*—— | |
| Shares issued | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0−100%0.0% | 0*—0.0% | 0*—— | 0*—— | 550—5450% | 0*—— | |
| Cash from financing activities | 61+123%44.6% | 67*—163% | −2.1*—−4.7% | −2.1—−7.9% | −1.8*−106%−7.4% | −1.8*−1059%−8.4% | −0.8*—−3.7% | 0−100%0.0% | 30*+130365%103472% | 0.2*—— | −2.1*—— | 561—5564% | 0.0*—— | |
| Exchange-rate effect on cash | −2.4—−1.7% | −0.8*—−1.9% | −0.2*−103%−0.4% | −2.0−156%−7.6% | 0.6*—2.4% | −3.6*−109%−16.9% | 5.7*+303%27.3% | 3.6—39.6% | −38*−491%−131779% | 38*—— | 1.4*—— | −1.2—−11.7% | 9.8*—— | |
| Change in cash | 159—116% | 74*—179% | 40*+44.2%88.6% | 27—102% | 18*—74.2% | −38*—−178% | 28*—134% | −132−125%−1465% | −430*—−1481834% | −48*—— | −53*—— | 519—5145% | −17*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Autolus Therapeutics sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product revenue, net(total)$74 M99%—
- License$1 M1.5%-89%
Business segments
- Reportable$75 M100%+645%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Autolus Therapeutics operates: 4 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 5 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇬🇧 UK | Headquarters2 subsidiaries | — |
| 🇩🇪 Germany | 1 subsidiary | — |
| 🇨🇭 Switzerland | 1 subsidiary | — |
| 🇺🇸 USA | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Autolus Therapeutics#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Restructuring 1 · Directors and officers 4 · Material agreement 3 · New debt 1 · Unregistered share sale 1 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Restructuring | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersResults announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Discuss Autolus Therapeutics#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 10 November 2026automatic update · Nov 10, 2026
Autolus Therapeutics announced results on 10 November 2026 (SEC Form 8-K, item 2.02).
- Mutual funds: 4 funds hold $3 millionautomatic update · Jun 30, 2026
4 mutual funds in 1 country hold shares of Autolus Therapeutics worth $3 million (funds' newest reports, up to 30 June 2026). Since their previous reports 4 funds added shares and 4 sold; on balance they sold $1 million. Share splits are not counted as trading.
How Autolus Therapeutics compares in Biotechnology
- Market cap$641 M · higher than 61% of 726
- Revenue$75 M · higher than 66% of 647
- Net margin-186.3% · higher than 30% of 408
- Revenue growth645.0% · higher than 96% of 438
- Price / sales4.7× · lower than 64% of 339
- Price / book3.6× · lower than 41% of 534
- FCF yield-47.2% · higher than 25% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Autolus Therapeutics🇬🇧 | $641 M | — | -186.3% | +645.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Autolus Therapeutics? Verify and update this profile — free
Show Autolus Therapeutics's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.